Shots:

• The approval is based on the P-III TAK-620-303 (SOLSTICE) trial evaluates the efficacy & safety of Maribavir (400mg, qd) vs IAT in a ratio (2:1) in 352 HCT and SOT recipients aged 12yrs. with CMV infection refractory with/out resistance- to one or a combination of the conventional antiviral therapies. The therapy will be available shortly
• The study showed that the proportion of patients achieved confirmed CMV DNA level
• Livtencity is an orally bioavailable anti-CMV compound & is the 1st antiviral agent that targets and inhibits the pUL97 protein kinase and its natural substrates

Click here to­ read full press release/ article

Ref: Takeda | Image: Takeda